<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35469167</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2589-5559</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>JHEP reports : innovation in hepatology</Title>
          <ISOAbbreviation>JHEP Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lipid alterations in chronic liver disease and liver cancer.</ArticleTitle>
        <Pagination>
          <StartPage>100479</StartPage>
          <MedlinePgn>100479</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100479</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhepr.2022.100479</ELocationID>
        <Abstract>
          <AbstractText>Lipids are a complex and diverse group of molecules with crucial roles in many physiological processes, as well as in the onset, progression, and maintenance of cancers. Fatty acids and cholesterol are the building blocks of lipids, orchestrating these crucial metabolic processes. In the liver, lipid alterations are prevalent as a cause and consequence of chronic hepatitis B and C virus infections, alcoholic hepatitis, and non-alcoholic fatty liver disease and steatohepatitis. Recent developments in lipidomics have also revealed that dynamic changes in triacylglycerols, phospholipids, sphingolipids, ceramides, fatty acids, and cholesterol are involved in the development and progression of primary liver cancer. Accordingly, the transcriptional landscape of lipid metabolism suggests a carcinogenic role of increasing fatty acids and sterol synthesis. However, limited mechanistic insights into the complex nature of the hepatic lipidome have so far hindered the development of effective therapies.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Paul</LastName>
            <ForeName>Bichitra</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Biotech Research &amp; Innovation Center (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lewinska</LastName>
            <ForeName>Monika</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Biotech Research &amp; Innovation Center (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andersen</LastName>
            <ForeName>Jesper B</ForeName>
            <Initials>JB</Initials>
            <AffiliationInfo>
              <Affiliation>Biotech Research &amp; Innovation Center (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JHEP Rep</MedlineTA>
        <NlmUniqueID>101761237</NlmUniqueID>
        <ISSNLinking>2589-5559</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ACC, acetyl-CoA carboxylase</Keyword>
        <Keyword MajorTopicYN="N">ACLY, ATP citrate lyase</Keyword>
        <Keyword MajorTopicYN="N">ALD, alcohol-related liver disease</Keyword>
        <Keyword MajorTopicYN="N">BAs, bile acids</Keyword>
        <Keyword MajorTopicYN="N">CCA, cholangiocarcinoma</Keyword>
        <Keyword MajorTopicYN="N">CPT, carnitine palmitoyltransferase</Keyword>
        <Keyword MajorTopicYN="N">Cer, ceramide(s)</Keyword>
        <Keyword MajorTopicYN="N">DNL, de novo lipogenesis</Keyword>
        <Keyword MajorTopicYN="N">ELOV1-6, elongation of very-long-chain fatty acids</Keyword>
        <Keyword MajorTopicYN="N">FA, fatty acid</Keyword>
        <Keyword MajorTopicYN="N">FABP, fatty acid-binding protein</Keyword>
        <Keyword MajorTopicYN="N">FADS2, fatty acid desaturase 2</Keyword>
        <Keyword MajorTopicYN="N">FAO, fatty acid oxidation</Keyword>
        <Keyword MajorTopicYN="N">FASN, fatty acid synthase</Keyword>
        <Keyword MajorTopicYN="N">FXR, farnesoid X receptor</Keyword>
        <Keyword MajorTopicYN="N">HCC, hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">HMGCR, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase</Keyword>
        <Keyword MajorTopicYN="N">HSCs, hepatic stellate cells</Keyword>
        <Keyword MajorTopicYN="N">LA, linoleic acid</Keyword>
        <Keyword MajorTopicYN="N">LPC, lysophosphatidylcholine</Keyword>
        <Keyword MajorTopicYN="N">LXR, liver X receptor</Keyword>
        <Keyword MajorTopicYN="N">MUFA, monounsaturated fatty acid</Keyword>
        <Keyword MajorTopicYN="N">NAFLD, non-alcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">NASH, non-alcoholic steatohepatitis</Keyword>
        <Keyword MajorTopicYN="N">Non-alcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">PC, phosphatidylcholine</Keyword>
        <Keyword MajorTopicYN="N">PPARs, peroxisome proliferator-activated receptors</Keyword>
        <Keyword MajorTopicYN="N">PSC, primary sclerosing cholangitis</Keyword>
        <Keyword MajorTopicYN="N">PUFA, polyunsaturated fatty acid</Keyword>
        <Keyword MajorTopicYN="N">S1P, sphingosine-1-phosphate</Keyword>
        <Keyword MajorTopicYN="N">SCD, stearoyl-CoA desaturase</Keyword>
        <Keyword MajorTopicYN="N">SE, sterol esters</Keyword>
        <Keyword MajorTopicYN="N">SFA, saturated fatty acid</Keyword>
        <Keyword MajorTopicYN="N">SM, sphingomyelin</Keyword>
        <Keyword MajorTopicYN="N">SREBP, sterol regulatory element-binding protein</Keyword>
        <Keyword MajorTopicYN="N">TERT, telomerase reverse transcriptase</Keyword>
        <Keyword MajorTopicYN="N">TG, triglycerides</Keyword>
        <Keyword MajorTopicYN="N">TLR, Toll-like receptor</Keyword>
        <Keyword MajorTopicYN="N">cholangiocarcinoma</Keyword>
        <Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">lipidomics</Keyword>
        <Keyword MajorTopicYN="N">metabolomics</Keyword>
      </KeywordList>
      <CoiStatement>Authors declare no conflicts of interest Please refer to the accompanying ICMJE disclosure forms for further details.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35469167</ArticleId>
        <ArticleId IdType="pmc">PMC9034302</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jhepr.2022.100479</ArticleId>
        <ArticleId IdType="pii">S2589-5559(22)00051-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24840647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30350310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M.A., Allen C., et al. Global Burden of Disease Liver Cancer C  The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–1691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5824275</ArticleId>
            <ArticleId IdType="pubmed">28983565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeOliveira M.L., Cunningham S.C., Cameron J.L., Kamangar F., Winter J.M., Lillemoe K.D., et al.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1877058</ArticleId>
            <ArticleId IdType="pubmed">17457168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakeeb A., Pitt H.A., Sohn T.A., Coleman J., Abrams R.A., Piantadosi S., et al.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–473. discussion 473-465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1235406</ArticleId>
            <ArticleId IdType="pubmed">8857851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanwal F., Kramer J., Asch S.M., Chayanupatkul M., Cao Y., El-Serag H.B. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996–1005 e1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28642197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estes C., Razavi H., Loomba R., Younossi Z., Sanyal A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5767767</ArticleId>
            <ArticleId IdType="pubmed">28802062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., et al.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7447603</ArticleId>
            <ArticleId IdType="pubmed">32606456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2140820</ArticleId>
            <ArticleId IdType="pubmed">19872213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnusson I., Schumann W.C., Bartsch G.E., Chandramouli V., Kumaran K., Wahren J., et al.  Noninvasive tracing of Krebs cycle metabolism in liver. J Biol Chem. 1991;266:6975–6984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2016309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diraison F., Large V., Brunengraber H., Beylot M. Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM. Diabetologia. 1998;41:212–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9498656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Large V., Brunengraber H., Odeon M., Beylot M. Use of labeling pattern of liver glutamate to calculate rates of citric acid cycle and gluconeogenesis. Am J Physiol. 1997;272:E51–E58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9038851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones J.G., Solomon M.A., Cole S.M., Sherry A.D., Malloy C.R. An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans. Am J Physiol Endocrinol Metab. 2001;281:E848–E856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11551863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones J.G., Solomon M.A., Sherry A.D., Jeffrey F.M., Malloy C.R. 13C NMR measurements of human gluconeogenic fluxes after ingestion of [U-13C]propionate, phenylacetate, and acetaminophen. Am J Physiol. 1998;275:E843–E852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9815005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satriano L., Lewinska M., Rodrigues P.M., Banales J.M., Andersen J.B. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16:748–766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31666728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvisi D.F., Wang C., Ho C., Ladu S., Lee S.A., Mattu S., et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140:1071–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3057329</ArticleId>
            <ArticleId IdType="pubmed">21147110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y., Chen J., Huang C., Li N., Zou L., Chia S.E., et al.  Comparison of hepatic and serum lipid signatures in hepatocellular carcinoma patients leads to the discovery of diagnostic and prognostic biomarkers. Oncotarget. 2018;9:5032–5043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5797031</ArticleId>
            <ArticleId IdType="pubmed">29435160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuerschner L., Moessinger C., Thiele C. Imaging of lipid biosynthesis: how a neutral lipid enters lipid droplets. Traffic. 2008;9:338–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18088320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–1503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4157349</ArticleId>
            <ArticleId IdType="pubmed">22037646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D., Zhao T., Long K., Wu M., Zhang Z. Triclosan down-regulates fatty acid synthase through microRNAs in HepG2 cells. Eur J Pharmacol. 2021;907:174261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34144025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S.Z., Ling Y., Yu L.X., Song Y.T., Chen X.F., Cao Q.Q., et al.  4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-alpha. Clin Transl Med. 2021;11:e379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8087947</ArticleId>
            <ArticleId IdType="pubmed">33931972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek A.E., Yu Y.A., He S., Wardell S.E., Chang C.Y., Kwon S., et al.  The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8:864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5636879</ArticleId>
            <ArticleId IdType="pubmed">29021522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu H., Tang B., Lang J., Du Y., Cao B., Jin L., et al.  High-fat diet promotes macrophage-mediated hepatic inflammation and aggravates diethylnitrosamine-induced hepatocarcinogenesis in mice. Front Nutr. 2020;7:585306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7701255</ArticleId>
            <ArticleId IdType="pubmed">33304918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima N., Hakomori S. Synergistic effect of two cell recognition systems: glycosphingolipid-glycosphingolipid interaction and integrin receptor interaction with pericellular matrix protein. Glycobiology. 1991;1:623–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1822242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X., Gross R.W. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res. 2003;44:1071–1079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12671038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zech T., Ejsing C.S., Gaus K., de Wet B., Shevchenko A., Simons K., et al.  Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 2009;28:466–476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2657588</ArticleId>
            <ArticleId IdType="pubmed">19177148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmelzer K., Fahy E., Subramaniam S., Dennis E.A. The lipid maps initiative in lipidomics. Methods Enzymol. 2007;432:171–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17954217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graessler J., Schwudke D., Schwarz P.E., Herzog R., Shevchenko A., Bornstein S.R. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One. 2009;4:e6261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2705678</ArticleId>
            <ArticleId IdType="pubmed">19603071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fahy E., Subramaniam S., Brown H.A., Glass C.K., Merrill A.H., Jr., Murphy R.C., et al.  A comprehensive classification system for lipids. J Lipid Res. 2005;46:839–861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15722563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendenhall C.L. Origin of hepatic triglyceride fatty acids: quantitative estimation of the relative contributions of linoleic acid by diet and adipose tissue in normal and ethanol-fed rats. J Lipid Res. 1972;13:177–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5016299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1087172</ArticleId>
            <ArticleId IdType="pubmed">15864352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diraison F., Moulin P., Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003;29:478–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14631324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burr G.O., Burr M.M. Nutrition classics from The Journal of Biological Chemistry 82:345-367, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutr Rev. 1973;31:248–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4586201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rieckenhoff I.G., Holman R.T., Burr G.O. Polyethenoid fatty acid metabolism; effect of dietary fat on polyethenoid fatty acids of rat tissues. Arch Biochem. 1949;20:331–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18108927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turley S.D., Andersen J.M., Dietschy J.M. Rates of sterol synthesis and uptake in the major organs of the rat in vivo. J Lipid Res. 1981;22:551–569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7276735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Repa J.J., Mangelsdorf D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11031244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the L. European Association for the Study of D. European Association for the Study of O  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27062661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Meer G., Voelker D.R., Feigenson G.W. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9:112–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2642958</ArticleId>
            <ArticleId IdType="pubmed">18216768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Barraza K.M., Beauchamp J.L. Cholesterol provides nonsacrificial protection of membrane lipids from chemical damage at air-water interface. Proc Natl Acad Sci U S A. 2018;115:3255–3260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879709</ArticleId>
            <ArticleId IdType="pubmed">29507237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wymann M.P., Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9:162–176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18216772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overkleeft H.S., Renkema G.H., Neele J., Vianello P., Hung I.O., Strijland A., et al.  Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem. 1998;273:26522–26527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9756888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown A.J., Goldsworthy S.M., Barnes A.A., Eilert M.M., Tcheang L., Daniels D., et al.  The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278:11312–11319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12496283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nilsson N.E., Kotarsky K., Owman C., Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun. 2003;303:1047–1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12684041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soroosh P., Wu J., Xue X., Song J., Sutton S.W., Sablad M., et al.  Oxysterols are agonist ligands of RORgammat and drive Th17 cell differentiation. Proc Natl Acad Sci U S A. 2014;111:12163–12168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4143045</ArticleId>
            <ArticleId IdType="pubmed">25092323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DuSell C.D., Umetani M., Shaul P.W., Mangelsdorf D.J., McDonnell D.P. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22:65–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194632</ArticleId>
            <ArticleId IdType="pubmed">17872378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umetani M., Domoto H., Gormley A.K., Yuhanna I.S., Cummins C.L., Javitt N.B., et al.  27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13:1185–1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17873880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falcon A., Doege H., Fluitt A., Tsang B., Watson N., Kay M.A., et al.  FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab. 2010;299:E384–E393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2944282</ArticleId>
            <ArticleId IdType="pubmed">20530735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doege H., Baillie R.A., Ortegon A.M., Tsang B., Wu Q., Punreddy S., et al.  Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology. 2006;130:1245–1258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16618416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doege H., Grimm D., Falcon A., Tsang B., Storm T.A., Xu H., et al.  Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem. 2008;283:22186–22192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2494916</ArticleId>
            <ArticleId IdType="pubmed">18524776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasui K., Harano Y., Mitsuyoshi H., Tsuji K., Endo M., Nakajima T., et al.  Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol. 2010;45:95–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19789836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado M.V., Oliveira A.G., Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21649726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connor C.L. Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism. Am J Pathol. 1938;14:347–364 349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1964950</ArticleId>
            <ArticleId IdType="pubmed">19970395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., Goto T., Westerbacka J., Sovijarvi A., et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023–3028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12107194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scherer T., Lindtner C., O'Hare J., Hackl M., Zielinski E., Freudenthaler A., et al.  Insulin regulates hepatic triglyceride secretion and lipid content via signaling in the brain. Diabetes. 2016;65:1511–1520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4878422</ArticleId>
            <ArticleId IdType="pubmed">26861781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holt H.B., Wild S.H., Wood P.J., Zhang J., Darekar A.A., Dewbury K., et al.  Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia. 2006;49:141–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16323001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng F., Jiang J., Zhang J., Yuan Y., Li K., Zhou B., et al.  The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling. Metabolism. 2021;117:154725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33571540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosch D.E., Yeh M.M. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. Hum Pathol. 2017;69:55–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28970141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banales J.M., Inarrairaegui M., Arbelaiz A., Milkiewicz P., Muntane J., Munoz-Bellvis L., et al.  Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology. 2019;70:547–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6767196</ArticleId>
            <ArticleId IdType="pubmed">30325540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sang C., Wang X., Zhou K., Sun T., Bian H., Gao X., et al.  Bile acid profiles are distinct among patients with different etiologies of chronic liver disease. J Proteome Res. 2021;20:2340–2351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33754726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J.M., Skill N.J., Maluccio M.A. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford) 2010;12:625–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2999790</ArticleId>
            <ArticleId IdType="pubmed">20961371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H.C., Chen Y.F., Hsu W.H., Yang C.W., Kao C.H., Tsai T.F. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 2012;5:952–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22659145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y.F., Fu S.L., Kao C.H., Yang C.W., Lin C.H., Hsu M.T., et al.  Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res. 2008;68:2033–2042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18339886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9734402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haberl E.M., Weiss T.S., Peschel G., Weigand K., Kohler N., Pauling J.K., et al.  Liver lipids of patients with hepatitis B and C and associated hepatocellular carcinoma. Int J Mol Sci. 2021:22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8744821</ArticleId>
            <ArticleId IdType="pubmed">35008458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arain S.Q., Talpur F.N., Channa N.A., Ali M.S., Afridi H.I. Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients. Lipids Health Dis. 2017;16:51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5333387</ArticleId>
            <ArticleId IdType="pubmed">28249586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao R., Cheng J., Fan C., Shi X., Cao Y., Sun B., et al.  Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma. Sci Rep. 2015;5:18175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4674760</ArticleId>
            <ArticleId IdType="pubmed">26658617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arain S.Q., Talpur F.N., Channa N.A., Ali M.S., Afridi H.I. Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B. Lipids Health Dis. 2018;17:36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5838863</ArticleId>
            <ArticleId IdType="pubmed">29506525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng H., Chen M., Lu S., Zhao L., Ji J., Gao H. Metabolic characterization of hepatitis B virus-related liver cirrhosis using NMR-based serum metabolomics. Metabolomics. 2017;13:121.</Citation>
        </Reference>
        <Reference>
          <Citation>Teng C.F., Hsieh W.C., Yang C.W., Su H.M., Tsai T.F., Sung W.C., et al.  A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis. Mol Carcinog. 2016;55:105–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25594851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofmann S., Krajewski M., Scherer C., Scholz V., Mordhorst V., Truschow P., et al.  Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1041–1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29885363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H.K., Kim S.Y., Yoo S.K., Choi Y.H., Cheong J. Fatty acids increase hepatitis B virus X protein stabilization and HBx-induced inflammatory gene expression. FEBS J. 2014;281:2228–2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24612645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui M., Xiao Z., Sun B., Wang Y., Zheng M., Ye L., et al.  Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4. Biochem Biophys Res Commun. 2014;445:651–655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24576478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Wu T., Hu D., Weng X., Wang X., Chen P.J., et al.  Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein. J Lipid Res. 2018;59:58–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5748497</ArticleId>
            <ArticleId IdType="pubmed">29133292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu T., Zheng X., Yang M., Zhao A., Li M., Chen T., et al.  Serum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients. Sci Rep. 2017;7:42710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5309878</ArticleId>
            <ArticleId IdType="pubmed">28198443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun J., Zhao Y., Qin L., Li K., Zhao Y., Sun H., et al.  Metabolomic profiles for HBV related hepatocellular carcinoma including alpha-fetoproteins positive and negative subtypes. Front Oncol. 2019;9:1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6803550</ArticleId>
            <ArticleId IdType="pubmed">31681602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lerat H., Kammoun H.L., Hainault I., Merour E., Higgs M.R., Callens C., et al.  Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem. 2009;284:33466–33474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2785191</ArticleId>
            <ArticleId IdType="pubmed">19808675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M., Zhang X.J., Feng K., He C., Li P., Hu Y.J., et al.  Dietary alpha-linolenic acid-rich flaxseed oil prevents against alcoholic hepatic steatosis via ameliorating lipid homeostasis at adipose tissue-liver axis in mice. Sci Rep. 2016;6:26826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4879538</ArticleId>
            <ArticleId IdType="pubmed">27220557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berk P.D., Zhou S., Bradbury M.W. Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings. Trans Am Clin Climatol Assoc. 2005;116:335–344. discussion 345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1473156</ArticleId>
            <ArticleId IdType="pubmed">16555625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S.L., Gordon R.E., Bradbury M., Stump D., Kiang C.L., Berk P.D. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells. Hepatology. 1998;27:1064–1074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9537447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong W., Zhao Y., Tang Y., Wei X., Shi X., Sun W., et al.  Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol. 2012;180:998–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3349880</ArticleId>
            <ArticleId IdType="pubmed">22234172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Israelsen M., Kim M., Suvitaival T., Madsen B.S., Hansen C.D., Torp N., et al.  Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Rep. 2021;3:100325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8350545</ArticleId>
            <ArticleId IdType="pubmed">34401690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji C., Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology. 2003;124:1488–1499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12730887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji C., Shinohara M., Vance D., Than T.A., Ookhtens M., Chan C., et al.  Effect of transgenic extrahepatic expression of betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver. Alcohol Clin Exp Res. 2008;32:1049–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596885</ArticleId>
            <ArticleId IdType="pubmed">18498552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You M., Fischer M., Deeg M.A., Crabb D.W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP) J Biol Chem. 2002;277:29342–29347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12036955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ooi G.J., Meikle P.J., Huynh K., Earnest A., Roberts S.K., Kemp W., et al.  Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021;75:524–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33887358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo R., Crespo J., Martinez-Arranz I., Banales J.M., Arias M., Minchole I., et al.  Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts. Hepatol Commun. 2018;2:807–820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6049064</ArticleId>
            <ArticleId IdType="pubmed">30027139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewinska M., Santos-Laso A., Arretxe E., Alonso C., Zhuravleva E., Jimenez-Aguero R., et al.  The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine. 2021;73:103661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8577325</ArticleId>
            <ArticleId IdType="pubmed">34740106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caussy C., Ajmera V.H., Puri P., Hsu C.L., Bassirian S., Mgdsyan M., et al.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut. 2019;68:1884–1892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8328048</ArticleId>
            <ArticleId IdType="pubmed">30567742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewinska M.S.-L.,A., Arretxe E., Alonso C., Zhuravleva E., Jimenez-Aguero R., Eizaguirre E., et al.   2021. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.</Citation>
        </Reference>
        <Reference>
          <Citation>Puri P., Daita K., Joyce A., Mirshahi F., Santhekadur P.K., Cazanave S., et al.  The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67:534–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5764808</ArticleId>
            <ArticleId IdType="pubmed">28696585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puri P., Baillie R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., et al.  A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17654743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15747110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuster S., Johnson C.D., Hennebelle M., Holtmann T., Taha A.Y., Kirpich I.A., et al.  Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice. J Lipid Res. 2018;59:1597–1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6121934</ArticleId>
            <ArticleId IdType="pubmed">30084831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Windt D.J., Sud V., Zhang H., Varley P.R., Goswami J., Yazdani H.O., et al.  Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2018;68:1347–1360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6173613</ArticleId>
            <ArticleId IdType="pubmed">29631332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown Z.J., Fu Q., Ma C., Kruhlak M., Zhang H., Luo J., et al.  Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4(+) T cell apoptosis promoting HCC development. Cell Death Dis. 2018;9:620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5966464</ArticleId>
            <ArticleId IdType="pubmed">29795111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C., Kesarwala A.H., Eggert T., Medina-Echeverz J., Kleiner D.E., Jin P., et al.  NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531:253–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4786464</ArticleId>
            <ArticleId IdType="pubmed">26934227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfister D., Nunez N.G., Pinyol R., Govaere O., Pinter M., Szydlowska M., et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8046670</ArticleId>
            <ArticleId IdType="pubmed">33762733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotronen A., Velagapudi V.R., Yetukuri L., Westerbacka J., Bergholm R., Ekroos K., et al.  Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia. 2009;52:684–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19214471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oresic M., Hyotylainen T., Kotronen A., Gopalacharyulu P., Nygren H., Arola J., et al.  Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia. 2013;56:2266–2274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3764317</ArticleId>
            <ArticleId IdType="pubmed">23824212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westerbacka J., Kotronen A., Fielding B.A., Wahren J., Hodson L., Perttila J., et al.  Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology. 2010;139:1961–1971 e1961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20600015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotronen A., Seppanen-Laakso T., Westerbacka J., Kiviluoto T., Arola J., Ruskeepaa A.L., et al.  Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes. 2009;58:203–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2606873</ArticleId>
            <ArticleId IdType="pubmed">18952834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorden D.L., Myers D.S., Ivanova P.T., Fahy E., Maurya M.R., Gupta S., et al.  Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res. 2015;56:722–736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340319</ArticleId>
            <ArticleId IdType="pubmed">25598080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Promrat K., Longato L., Wands J.R., de la Monte S.M. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res. 2011;41:754–762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4550290</ArticleId>
            <ArticleId IdType="pubmed">21794038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luukkonen P.K., Zhou Y., Sadevirta S., Leivonen M., Arola J., Oresic M., et al.  Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;64:1167–1175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26780287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apostolopoulou M., Gordillo R., Koliaki C., Gancheva S., Jelenik T., De Filippo E., et al.  Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care. 2018;41:1235–1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29602794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masoodi M., Gastaldelli A., Hyotylainen T., Arretxe E., Alonso C., Gaggini M., et al.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Xia J.Y., Holland W.L., Kusminski C.M., Sun K., Sharma A.X., Pearson M.J., et al.  Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 2015;22:266–278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4527941</ArticleId>
            <ArticleId IdType="pubmed">26190650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaurasia B., Tippetts T.S., Mayoral Monibas R., Liu J., Li Y., Wang L., et al.  Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science. 2019;365:386–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6787918</ArticleId>
            <ArticleId IdType="pubmed">31273070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasarathy S., Yang Y., McCullough A.J., Marczewski S., Bennett C., Kalhan S.C. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23:382–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3493151</ArticleId>
            <ArticleId IdType="pubmed">21448070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aranha M.M., Cortez-Pinto H., Costa A., da Silva I.B., Camilo M.E., de Moura M.C., et al.  Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20:519–525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18467911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouzaki M., Wang A.Y., Bandsma R., Comelli E.M., Arendt B.M., Zhang L., et al.  Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One. 2016;11</Citation>
        </Reference>
        <Reference>
          <Citation>Chavez-Talavera O., Tailleux A., Lefebvre P., Staels B. Bile acid control of metabolism and inflammation in obesity, Type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152:1679–1694 e1673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28214524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Cai B., Yang X., Sonubi O.O., Zheng Z., Ramakrishnan R., et al.  Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis. Cell Metab. 2020;31:969–986 e967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7313619</ArticleId>
            <ArticleId IdType="pubmed">32259482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell L.N., Wulff J., Comerford M., Vuppalanchi R., Chalasani N. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int. 2015;35:263–274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4293304</ArticleId>
            <ArticleId IdType="pubmed">25181933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trottier J., Bialek A., Caron P., Straka R.J., Heathcote J., Milkiewicz P., et al.  Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis. 2012;44:303–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22169272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L., Wang Q., Yin P., Xing W., Wu Z., Chen S., et al.  Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem. 2012;403:203–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22349331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muir K., Hazim A., He Y., Peyressatre M., Kim D.Y., Song X., et al.  Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 2013;73:4722–4731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3855016</ArticleId>
            <ArticleId IdType="pubmed">23749645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho Y., Cho E.J., Yoo J.J., Chang Y., Chung G.E., Jeong S.M., et al.  Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers (Basel) 2021;13</Citation>
        </Reference>
        <Reference>
          <Citation>Padthaisong S., Phetcharaburanin J., Klanrit P., Li J.V., Namwat N., Khuntikeo N., et al.  Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma. Cancer Metab. 2021;9:30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8335966</ArticleId>
            <ArticleId IdType="pubmed">34348794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ismail I.T., Elfert A., Helal M., Salama I., El-Said H., Fiehn O. Remodeling lipids in the transition from chronic liver disease to hepatocellular carcinoma. Cancers (Basel) 2020;13</Citation>
        </Reference>
        <Reference>
          <Citation>Vlock E.M., Karanjit S., Talmon G., Farazi P.A. Reduction of polyunsaturated fatty acids with tumor progression in a lean non-alcoholic steatohepatitis-associated hepatocellular carcinoma mouse model. J Cancer. 2020;11:5536–5546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7477439</ArticleId>
            <ArticleId IdType="pubmed">32913449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grammatikos G., Schoell N., Ferreiros N., Bon D., Herrmann E., Farnik H., et al.  Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma. Oncotarget. 2016;7:18095–18105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4951274</ArticleId>
            <ArticleId IdType="pubmed">26933996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guri Y., Colombi M., Dazert E., Hindupur S.K., Roszik J., Moes S., et al.  mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell. 2017;32:807–823 e812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29232555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirose Y., Nagahashi M., Katsuta E., Yuza K., Miura K., Sakata J., et al.  Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep. 2018;8:10814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6050292</ArticleId>
            <ArticleId IdType="pubmed">30018456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J.C., Wang E.Y., Yi Y., Thakur A., Tsai S.H., Hoodless P.A. S1P stimulates proliferation by upregulating CTGF expression through S1PR2-mediated YAP activation. Mol Cancer Res. 2018;16:1543–1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29903770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao M., Chen Z., Xu Y., Zhao Y., Zha R., Huang S., et al.  Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int. 2012;32:331–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22098666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Y., Yao X., Chen L., Yan Z., Liu J., Zhang Y., et al.  Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-beta autocrine loop. Oncotarget. 2016;7:63324–63337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5325366</ArticleId>
            <ArticleId IdType="pubmed">27556509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokota T., Nojima H., Kuboki S., Yoshitomi H., Furukawa K., Takayashiki T., et al.  Sphingosine-1-phosphate Receptor-1 promotes vascular invasion and EMT in hepatocellular carcinoma. J Surg Res. 2021;259:200–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33307511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S.L., Liu L. microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. Exp Ther Med. 2015;9:579–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4280928</ArticleId>
            <ArticleId IdType="pubmed">25574238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida T., Tsuchiya A., Kumagai M., Takeuchi S., Nojiri S., Watanabe T., et al.  Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH. Biochem Biophys Res Commun. 2020;530:665–672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32768187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J., Tian Y., Zheng R., Li L., Qiu F. Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma. Oncol Lett. 2019;18:1530–1538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6607111</ArticleId>
            <ArticleId IdType="pubmed">31423220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krautbauer S., Meier E.M., Rein-Fischboeck L., Pohl R., Weiss T.S., Sigruener A., et al.  Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma. Biochim Biophys Acta. 2016;1861:1767–1774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27570113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall Z., Chiarugi D., Charidemou E., Leslie J., Scott E., Pellegrinet L., et al.  Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma. Hepatology. 2021;73:1028–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32460431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cotte A.K., Cottet V., Aires V., Mouillot T., Rizk M., Vinault S., et al.  Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients. Oncotarget. 2019;10:2161–2172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6481329</ArticleId>
            <ArticleId IdType="pubmed">31040908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Britten C.D., Garrett-Mayer E., Chin S.H., Shirai K., Ogretmen B., Bentz T.A., et al.  A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017;23:4642–4650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5559328</ArticleId>
            <ArticleId IdType="pubmed">28420720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi W., Zhang S., Ma D., Yan D., Zhang G., Cao Y., et al.  Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma. Front Oncol. 2020;10:694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7327090</ArticleId>
            <ArticleId IdType="pubmed">32670862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z., Zhang Z., Mei H., Mao J., Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int. 2020;14:544–555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7366576</ArticleId>
            <ArticleId IdType="pubmed">32504407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L., Ding L., Yin P., Lu X., Wang X., Niu J., et al.  Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. J Proteome Res. 2012;11:5433–5442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22946841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang J.Q., Teoh N., Xu L., Pok S., Li X., Chu E.S.H., et al.  Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat Commun. 2018;9:4490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6203711</ArticleId>
            <ArticleId IdType="pubmed">30367044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchida T., Lee Y.A., Fujiwara N., Ybanez M., Allen B., Martins S., et al.  A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69:385–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6054570</ArticleId>
            <ArticleId IdType="pubmed">29572095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong Y.J., Qiu T.Y., Ng G.K., Zheng Q., Teo E.K. Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55:615–623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33606427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavu S., Therneau T.M., Harmsen W.S., Mara K.C., Wongjarupong N., Hassan M., et al.  Effect of statins on the risk of extrahepatic cholangiocarcinoma. Hepatology. 2020;72:1298–1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8155698</ArticleId>
            <ArticleId IdType="pubmed">32119126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thrift A.P., Natarajan Y., Liu Y., El-Serag H.B. Statin use after diagnosis of hepatocellular carcinoma is associated with decreased mortality. Clin Gastroenterol Hepatol. 2019;17:2117–2125 e2113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6612541</ArticleId>
            <ArticleId IdType="pubmed">30625400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan D.E., Serper M.A., Mehta R., Fox R., John B., Aytaman A., et al.  Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology. 2019;156:1693–1706 e1612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30660733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin W.H., Yang Z.S., Li M., Chen Y., Zhao X.F., Qin Y.Y., et al.  High serum levels of cholesterol increase antitumor functions of nature killer cells and reduce growth of liver tumors in mice. Gastroenterology. 2020;158:1713–1727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31972238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreotti G., Chen J., Gao Y.T., Rashid A., Chang S.C., Shen M.C., et al.  Serum lipid levels and the risk of biliary tract cancers and biliary stones: a population-based study in China. Int J Cancer. 2008;122:2322–2329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2860727</ArticleId>
            <ArticleId IdType="pubmed">18076041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas C.E., Luu H.N., Wang R., Xie G., Adams-Haduch J., Jin A., et al.  Association between pre-diagnostic serum bile acids and hepatocellular carcinoma: the Singapore Chinese health study. Cancers (Basel) 2021;13</Citation>
        </Reference>
        <Reference>
          <Citation>Sydor S., Best J., Messerschmidt I., Manka P., Vilchez-Vargas R., Brodesser S., et al.  Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin Transl Gastroenterol. 2020;11:e00131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7145043</ArticleId>
            <ArticleId IdType="pubmed">32352707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu L., Feng J., Li J., Yu Q., Ji J., Wu J., et al.  The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother. 2021;133:111036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33378947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C., Xie C., Li F., Zhang L., Nichols R.G., Krausz K.W., et al.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125:386–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4382255</ArticleId>
            <ArticleId IdType="pubmed">25500885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garrido A., Kim E., Teijeiro A., Sanchez Sanchez P., Gallo R., Nair A., et al.  Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis. J Hepatol. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Mencarelli A., Renga B., Migliorati M., Cipriani S., Distrutti E., Santucci L., et al.  The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol. 2009;183:6657–6666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19880446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Yang Z., Shi Z., Zhu Z., Li C., Du Z., et al.  Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls. J Steroid Biochem Mol Biol. 2021;205:105775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33130021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai J., Wang H., Shi Y., Dong Y., Zhang Y., Wang J. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol. 2011;4:41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3207959</ArticleId>
            <ArticleId IdType="pubmed">21988803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai J., Wang H., Dong Y., Zhang Y., Wang J. Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway. Cancer Invest. 2013;31:111–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23362950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemp C.J., Leary C.N., Drinkwater N.R. Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc Natl Acad Sci U S A. 1989;86:7505–7509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC298093</ArticleId>
            <ArticleId IdType="pubmed">2798421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrick J.L., McMenamin U.C., Zhang X., Zeleniuch-Jacquotte A., Wactawski-Wende J., Simon T.G., et al.  Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank. Br J Cancer. 2020;123:316–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7374167</ArticleId>
            <ArticleId IdType="pubmed">32376888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Q., Guo P., Mu K., Zhang Y., Zhao W., Huai W., et al.  Estrogen suppresses hepatocellular carcinoma cells through ERbeta-mediated upregulation of the NLRP3 inflammasome. Lab Invest. 2015;95:804–816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26006022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaewlert W., Sakonsinsiri C., Namwat N., Sawanyawisuth K., Ungarreevittaya P., Khuntikeo N., et al.  The importance of CYP19A1 in estrogen receptor-positive cholangiocarcinoma. Horm Cancer. 2018;9:408–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30284180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunsawong T., Singsuksawat E., In-chon N., Chawengrattanachot W., Thuwajit C., Sripa B., et al.  Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. J Cancer Res Clin Oncol. 2012;138:1311–1320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22476540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawar P., Ma L., Byon C.H., Liu H., Ahn E.Y., Jhala N., et al.  Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res. 2009;15:1288–1296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2905314</ArticleId>
            <ArticleId IdType="pubmed">19228732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGlynn K.A., Sahasrabuddhe V.V., Campbell P.T., Graubard B.I., Chen J., Schwartz L.M., et al.  Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer. 2015;112:1266–1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4385955</ArticleId>
            <ArticleId IdType="pubmed">25742475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Ramadori P., Pfister D., Seehawer M., Zender L., Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Liu X., Liu X., Shi Q., Fan X., Qi K. Association of telomere length and telomerase methylation with n-3 fatty acids in preschool children with obesity. BMC Pediatr. 2021;21:24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7788823</ArticleId>
            <ArticleId IdType="pubmed">33413203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alves-Paiva R.M., Kajigaya S., Feng X., Chen J., Desierto M., Wong S., et al.  Telomerase enzyme deficiency promotes metabolic dysfunction in murine hepatocytes upon dietary stress. Liver Int. 2018;38:144–154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5741503</ArticleId>
            <ArticleId IdType="pubmed">28741793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet J.M., Kelley R.K., Villanueva A., Singal A.G., Pikarsky E., Roayaie S., et al.  Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33479224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H., Ng R., Chen X., Steer C.J., Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2016;65:1850–1860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4882277</ArticleId>
            <ArticleId IdType="pubmed">26282675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo W., Zhong W., Hao L., Dong H., Sun X., Yue R., et al.  Fatty acids inhibit LAMP2-mediated autophagy flux via activating ER stress pathway in alcohol-related liver disease. Cell Mol Gastroenterol Hepatol. 2021;12:1599–1615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8536789</ArticleId>
            <ArticleId IdType="pubmed">34284164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nath A., Li I., Roberts L.R., Chan C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4589791</ArticleId>
            <ArticleId IdType="pubmed">26424075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao L., Han C., Song K., Zhang J., Lim K., Wu T. Omega-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting miR-26a/b expression. Cancer Res. 2015;75:1388–1398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383692</ArticleId>
            <ArticleId IdType="pubmed">25691459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fekry B., Jeffries K.A., Esmaeilniakooshkghazi A., Szulc Z.M., Knagge K.J., Kirchner D.R., et al.  C16-ceramide is a natural regulatory ligand of p53 in cellular stress response. Nat Commun. 2018;9:4149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6175828</ArticleId>
            <ArticleId IdType="pubmed">30297838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uranbileg B., Ikeda H., Kurano M., Enooku K., Sato M., Saigusa D., et al.  Increased mRNA levels of sphingosine kinases and S1P lyase and reduced levels of S1P were observed in hepatocellular carcinoma in association with poorer differentiation and earlier recurrence. PLoS One. 2016;11:e0149462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4757388</ArticleId>
            <ArticleId IdType="pubmed">26886371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin X., Zafrullah M., Lee H., Haimovitz-Friedman A., Fuks Z., Kolesnick R. A ceramide-binding C1 domain mediates kinase suppressor of ras membrane translocation. Cell Physiol Biochem. 2009;24:219–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2978518</ArticleId>
            <ArticleId IdType="pubmed">19710537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skill N.J., Scott R.E., Wu J., Maluccio M.A. Hepatocellular carcinoma associated lipid metabolism reprogramming. J Surg Res. 2011;169:51–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19932908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M., Liu Z., Wang C., Yao B., Zheng X. EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling. Oncotarget. 2017;8:66154–66168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5630400</ArticleId>
            <ArticleId IdType="pubmed">29029500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu B., Shi S., Ma Y.G., Fan F., Yao Z.Z. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway. Hepatogastroenterology. 2012;59:785–789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22020916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakakima Y., Hayakawa A., Nakao A. Phosphatidylcholine induces growth inhibition of hepatic cancer by apoptosis via death ligands. Hepatogastroenterology. 2009;56:481–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19579625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Zheng Z., Caviglia J.M., Corey K.E., Herfel T.M., Cai B., et al.  Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 2016;24:848–862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5226184</ArticleId>
            <ArticleId IdType="pubmed">28068223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brindley P.J., Bachini M., Ilyas S.I., Khan S.A., Loukas A., Sirica A.E., et al.  Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7:65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34504109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gouw A.M., Eberlin L.S., Margulis K., Sullivan D.K., Toal G.G., Tong L., et al.  Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A. 2017;114:4300–4305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5410819</ArticleId>
            <ArticleId IdType="pubmed">28400509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Y., Sun S., Wang J., Fei F., Dong Z., Ke A.W., et al.  Canonical Wnt signaling remodels lipid metabolism in zebrafish hepatocytes following ras oncogenic insult. Cancer Res. 2018;78:5548–5560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30065049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L.L., Wang W.J. p53 regulates lipid metabolism in cancer. Int J Biol Macromol. 2021;192:45–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34619274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yahagi N., Shimano H., Matsuzaka T., Najima Y., Sekiya M., Nakagawa Y., et al.  p53 Activation in adipocytes of obese mice. J Biol Chem. 2003;278:25395–25400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12734185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon S.H., Huang C.H., Houlihan S.L., Regunath K., Freed-Pastor W.A., Morris JPt, et al.  p53 represses the mevalonate pathway to mediate tumor suppression. Cell. 2019;176:564–580 e519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6483089</ArticleId>
            <ArticleId IdType="pubmed">30580964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assaily W., Rubinger D.A., Wheaton K., Lin Y., Ma W., Xuan W., et al.  ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol Cell. 2011;44:491–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22055193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derdak Z., Villegas K.A., Harb R., Wu A.M., Sousa A., Wands J.R. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol. 2013;58:785–791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3612370</ArticleId>
            <ArticleId IdType="pubmed">23211317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo Y., Wang Y., Zhang L., Yang L., Zhou M., Li X., et al.  The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer. 2019;10:3789–3797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6636296</ArticleId>
            <ArticleId IdType="pubmed">31333796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S., Tang S. WNT/beta-catenin signaling in the development of liver cancers. Biomed Pharmacother. 2020;132:110851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33080466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senni N., Savall M., Cabrerizo Granados D., Alves-Guerra M.C., Sartor C., Lagoutte I., et al.  beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut. 2019;68:322–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29650531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Viscarra J., Kim S.J., Sul H.S. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015;16:678–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4884795</ArticleId>
            <ArticleId IdType="pubmed">26490400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997;94:4312–4317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC20719</ArticleId>
            <ArticleId IdType="pubmed">9113986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X.L., Sun Y.F., Wang B.L., Shen M.N., Zhou Y., Chen J.W., et al.  Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. BMC Cancer. 2019;19:760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6676608</ArticleId>
            <ArticleId IdType="pubmed">31370822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudalska R., Harbig J., Snaebjornsson M.T., Klotz S., Zwirner S., Taranets L., et al.  LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer. 2021;2:201–217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35122079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu Y., Tamura T., Kemmochi A., Owada Y., Ozawa Y., Hisakura K., et al.  Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model. J Gastroenterol Hepatol. 2021;36:800–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7983938</ArticleId>
            <ArticleId IdType="pubmed">32870526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng X., Chen Z., Farshidfar F., Xu X., Lorenzi P.L., Wang Y., et al.  Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep. 2018;23:255–269.e254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5916795</ArticleId>
            <ArticleId IdType="pubmed">29617665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ally A., Balasundaram M., Carlsen R., Chuah E., Clarke A., Dhalla N., et al.  Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–1341.e1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5680778</ArticleId>
            <ArticleId IdType="pubmed">28622513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budhu A., Roessler S., Zhao X., Yu Z., Forgues M., Ji J., et al.  Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144:1066–1075 e1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3633738</ArticleId>
            <ArticleId IdType="pubmed">23376425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., et al.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001;98:7522–7527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC34701</ArticleId>
            <ArticleId IdType="pubmed">11390966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merkel M., Weinstock P.H., Chajek-Shaul T., Radner H., Yin B., Breslow J.L., et al.  Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia. J Clin Invest. 1998;102:893–901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC508954</ArticleId>
            <ArticleId IdType="pubmed">9727057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo X., Zheng E., Wei L., Zeng H., Qin H., Zhang X., et al.  The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 2021;12:328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7997878</ArticleId>
            <ArticleId IdType="pubmed">33771982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson C.M., Stahl A. SLC27 fatty acid transport proteins. Mol Aspects Med. 2013;34:516–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3602789</ArticleId>
            <ArticleId IdType="pubmed">23506886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L., Che L., Tharp K.M., Park H.M., Pilo M.G., Cao D., et al.  Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016;63:1900–1913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874885</ArticleId>
            <ArticleId IdType="pubmed">26910791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebouissou S., Nault J.C. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020;72:215–229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31954487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y., Tao J., Calvisi D.F., Chen X. Role of lipogenesis rewiring in hepatocellular carcinoma. Semin Liver Dis. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Nelson M.E., Lahiri S., Chow J.D., Byrne F.L., Hargett S.R., Breen D.S., et al.  Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival. Nat Commun. 2017;8:14689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5424065</ArticleId>
            <ArticleId IdType="pubmed">28290443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Q., Chen C.A., Yang W., Liang D., Lv H.W., Lv G.S., et al.  ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/beta-catenin signaling pathway. Hepatobiliary Pancreat Dis Int. 2021;20:251–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33129711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lally J.S.V., Ghoshal S., DePeralta D.K., Moaven O., Wei L., Masia R., et al.  Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29:174–182 e175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6643297</ArticleId>
            <ArticleId IdType="pubmed">30244972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M.D., Wu H., Fu G.B., Zhang H.L., Zhou X., Tang L., et al.  Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. Hepatology. 2016;63:1272–1286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26698170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yahagi N., Shimano H., Hasegawa K., Ohashi K., Matsuzaka T., Najima Y., et al.  Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer. 2005;41:1316–1322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15869874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syed-Abdul M.M., Parks E.J., Gaballah A.H., Bingham K., Hammoud G.M., Kemble G., et al.  Fatty acid synthase inhibitor TVB-2640 reduces hepatic de Novo lipogenesis in males with metabolic abnormalities. Hepatology. 2020;72:103–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31630414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu L., Zhu Y., Lin X., Tan X., Lu B., Li Y. Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene. 2020;39:2437–2449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31974474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng G., Palanisamy A.P., Evans Z.P., Sutter A.G., Jin L., Singh I., et al.  Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice. PLoS One. 2013;8:e75980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3785413</ArticleId>
            <ArticleId IdType="pubmed">24086674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassim S., Raymond V.A., Dehbidi-Assadzadeh L., Lapierre P., Bilodeau M. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle. 2018;17:903–916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6056217</ArticleId>
            <ArticleId IdType="pubmed">29633904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geidl-Flueck B., Hochuli M., Nemeth A., Eberl A., Derron N., Kofeler H.C., et al.  Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial. J Hepatol. 2021;75:46–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33684506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Che L., Chi W., Qiao Y., Zhang J., Song X., Liu Y., et al.  Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69:177–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6943247</ArticleId>
            <ArticleId IdType="pubmed">30954949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding H., Liu J., Wang C., Su Y. NONO promotes hepatocellular carcinoma progression by enhancing fatty acids biosynthesis through interacting with ACLY mRNA. Cancer Cell Int. 2020;20:425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7461318</ArticleId>
            <ArticleId IdType="pubmed">32884448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao Q., Li T., Zhang X., Gao P., Qiao P., Li S., et al.  Expression and roles of fatty acid synthase in hepatocellular carcinoma. Oncol Rep. 2014;32:2471–2476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25231933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim C.W., Addy C., Kusunoki J., Anderson N.N., Deja S., Fu X., et al.  Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab. 2017;26:394–406 e396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5603267</ArticleId>
            <ArticleId IdType="pubmed">28768177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates J., Vijayakumar A., Ghoshal S., Marchand B., Yi S., Kornyeyev D., et al.  Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol. 2020;73:896–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32376414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow J.D., Lawrence R.T., Healy M.E., Dominy J.E., Liao J.A., Breen D.S., et al.  Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol Metab. 2014;3:419–431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4060285</ArticleId>
            <ArticleId IdType="pubmed">24944901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L., Pilo G.M., Li X., Cigliano A., Latte G., Che L., et al.  Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2016;64:333–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4718802</ArticleId>
            <ArticleId IdType="pubmed">26476289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B., Zhou B.H., Xiao M., Li H., Guo L., Wang M.X., et al.  KDM5C represses FASN-mediated lipid metabolism to exert tumor suppressor activity in intrahepatic cholangiocarcinoma. Front Oncol. 2020;10:1025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7344276</ArticleId>
            <ArticleId IdType="pubmed">32714863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang G.M., Jiang Q.H., Cai C., Qu M., Shen W. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway. Cancer Lett. 2015;358:180–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25528629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falvella F.S., Pascale R.M., Gariboldi M., Manenti G., De Miglio M.R., Simile M.M., et al.  Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis. 2002;23:1933–1936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12419843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vriens K., Christen S., Parik S., Broekaert D., Yoshinaga K., Talebi A., et al.  Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566:403–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6390935</ArticleId>
            <ArticleId IdType="pubmed">30728499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Y.C., Feng Y.H., Wu H.T., Huang Y.S., Tung C.L., Wu P., et al.  Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression. Sci Rep. 2018;8:6586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5920119</ArticleId>
            <ArticleId IdType="pubmed">29700319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Li T., Jin Y., Shen J. Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression. Biomed Pharmacother. 2019;115:108950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31078041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Rosa Rodriguez M.A., Deng L., Gemmink A., van Weeghel M., Aoun M.L., Warnecke C., et al.  Hypoxia-inducible lipid droplet-associated induces DGAT1 and promotes lipid storage in hepatocytes. Mol Metab. 2021;47:101168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7881268</ArticleId>
            <ArticleId IdType="pubmed">33465519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.H., Nagappan A., Jung D.Y., Suh N., Jung M.H. Histone demethylase KDM7A contributes to the development of hepatic steatosis by targeting diacylglycerol acyltransferase 2. Int J Mol Sci. 2021;22</Citation>
        </Reference>
        <Reference>
          <Citation>Shen X., Liang X., Ji X., You J., Zhuang X., Song Y., et al.  CD36 and DGAT2 facilitate the lipid-lowering effect of chitooligosaccharides via fatty acid intake and triglyceride synthesis signaling. Food Funct. 2021;12:8681–8693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34351342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang S., Sung P.S., Lee J., Park J., Shin E.C., Choi C. Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells. J Cell Mol Med. 2016;20:38–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4717863</ArticleId>
            <ArticleId IdType="pubmed">26493024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McFie P.J., Chumala P., Katselis G.S., Stone S.J. DGAT2 stability is increased in response to DGAT1 inhibition in gene edited HepG2 cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866:158991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34116261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yenilmez B., Wetoska N., Kelly M., Echeverria D., Min K., Lifshitz L., et al.  An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Mol Ther. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Ramon-Krauel M., Pentinat T., Bloks V.W., Cebria J., Ribo S., Perez-Wienese R., et al.  Epigenetic programming at the Mogat1 locus may link neonatal overnutrition with long-term hepatic steatosis and insulin resistance. FASEB J. 2018</Citation>
        </Reference>
        <Reference>
          <Citation>Wolf Greenstein A., Majumdar N., Yang P., Subbaiah P.V., Kineman R.D., Cordoba-Chacon J. Hepatocyte-specific, PPARgamma-regulated mechanisms to promote steatosis in adult mice. J Endocrinol. 2017;232:107–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5120553</ArticleId>
            <ArticleId IdType="pubmed">27799461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall A.M., Kou K., Chen Z., Pietka T.A., Kumar M., Korenblat K.M., et al.  Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver. J Lipid Res. 2012;53:990–999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3329399</ArticleId>
            <ArticleId IdType="pubmed">22394502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y., Temkin S.M., Hawkridge A.M., Guo C., Wang W., Wang X.Y., et al.  Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6240910</ArticleId>
            <ArticleId IdType="pubmed">30102953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farshidfar F., Zheng S., Gingras M.C., Newton Y., Shih J., Robertson A.G., et al.  Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18:2780–2794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5493145</ArticleId>
            <ArticleId IdType="pubmed">28297679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. Electronic address wbe. Cancer Genome Atlas Research N  Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–1341 e1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5680778</ArticleId>
            <ArticleId IdType="pubmed">28622513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara N., Nakagawa H., Enooku K., Kudo Y., Hayata Y., Nakatsuka T., et al.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018;67:1493–1504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6039238</ArticleId>
            <ArticleId IdType="pubmed">29437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Romero F., Mestre D., Aurrekoetxea I., O'Rourke C.J., Andersen J.B., Woodhoo A., et al.  E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment. Cancer Res. 2021;81:2874–2887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33771899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan P., Mu J., Wang Z., Ma S., Da X., Song J., et al.  Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation. Cell Death Dis. 2021;12:361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8024385</ArticleId>
            <ArticleId IdType="pubmed">33824298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma A.P.Y., Yeung C.L.S., Tey S.K., Mao X., Wong S.W.K., Ng T.H., et al.  Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant Cav1/SREBP-1 signaling. Cancer Res. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao X., Qin W., Jiang Y., Yang Z., Yuan B., Dai R., et al.  ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma. NPJ Precis Oncol. 2020;4:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7096519</ArticleId>
            <ArticleId IdType="pubmed">32219176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawata S., Takaishi K., Nagase T., Ito N., Matsuda Y., Tamura S., et al.  Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 1990;50:3270–3273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2159376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomacha J., Dokduang H., Padthaisong S., Namwat N., Klanrit P., Phetcharaburanin J., et al.  Targeting fatty acid synthase modulates metabolic pathways and inhibits cholangiocarcinoma cell progression. Front Pharmacol. 2021;12:696961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8371458</ArticleId>
            <ArticleId IdType="pubmed">34421595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23063971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D., Wong C.C., Fu L., Chen H., Zhao L., Li C., et al.  Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Z., Chen L., Sun B., Liu D., He Y., Qi L., et al.  LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Mol Metab. 2021;51:101230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8102998</ArticleId>
            <ArticleId IdType="pubmed">33823318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manieri E., Folgueira C., Rodriguez M.E., Leiva-Vega L., Esteban-Lafuente L., Chen C., et al.  JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proc Natl Acad Sci U S A. 2020;117:16492–16499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7368313</ArticleId>
            <ArticleId IdType="pubmed">32601222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao R., Cheng J., Fan C., Shi X., Cao Y., Sun B., et al.  Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma. Scientific Rep. 2015;5</Citation>
        </Reference>
        <Reference>
          <Citation>Lieber C.S., Jones D.P., Decarli L.M. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest. 1965;44:1009–1021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC292581</ArticleId>
            <ArticleId IdType="pubmed">14322019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu K., Wang C., Gao Y., Fan S., Zhang H., Sun J., et al.  Metabolomics and lipidomics reveal the effect of hepatic Vps33b deficiency on bile acids and lipids metabolism. Front Pharmacol. 2019;10:276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6439481</ArticleId>
            <ArticleId IdType="pubmed">30967781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan L.B., Liao J., Han N., Zhou L.Y., Wang X.E., Wang Y.J., et al.  Association between hepatitis B virus infection and metabolic syndrome in Southwest China: a cross-sectional study. Sci Rep. 2020;10:6738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7174346</ArticleId>
            <ArticleId IdType="pubmed">32317690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butt A.A., Yan P., Simon T.G., Chung R.T., Abou-Samra A.B., Team Es  Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis. 2015;15:510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4642733</ArticleId>
            <ArticleId IdType="pubmed">26558512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q., He X.D., Yu L., Liu W., Tao L.Y. The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev. 2012;13:1963–1969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22901155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Li M., Wang X., Dang Z., Jiang Y., Wang X., et al.  Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis. Lipids Health Dis. 2018;17:248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6220457</ArticleId>
            <ArticleId IdType="pubmed">30400953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ressom H.W., Xiao J.F., Tuli L., Varghese R.S., Zhou B., Tsai T.H., et al.  Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta. 2012;743:90–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3419576</ArticleId>
            <ArticleId IdType="pubmed">22882828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang Q., Liu H., Zhang T., Jiang Y., Xing H., Zhang H. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma. Mol Biosyst. 2016;12:334–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26646623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto M., Yashiro H., Ogino H., Aoyama K., Nambu T., Nakamura S., et al.  Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. PLoS One. 2020;15:e0228212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6986730</ArticleId>
            <ArticleId IdType="pubmed">31990961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alkhouri N., Lawitz E., Noureddin M., DeFronzo R., Shulman G.I. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) Expert Opin Investig Drugs. 2020;29:135–141.</Citation>
        </Reference>
        <Reference>
          <Citation>Lawitz E.J., Coste A., Poordad F., Alkhouri N., Loo N., McColgan B.J., et al.  Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2018;16:1983–1991 e1983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29705265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiede K., Miao W., Blanchette H.S., Beysen C., Harriman G., Harwood H.J., Jr., et al.  Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology. 2017;66:324–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5599970</ArticleId>
            <ArticleId IdType="pubmed">28470676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loomba R., Mohseni R., Lucas K.J., Gutierrez J.A., Perry R.G., Trotter J.F., et al.  TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology. 2021;161:1475–1486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34310978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y.H., Kim J.H., Kim S.R., Jin H.Y., Rhee E.J., Cho Y.M., et al.  Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017;32:60–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5143300</ArticleId>
            <ArticleId IdType="pubmed">27914133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoneda M., Endo H., Nozaki Y., Tomimoto A., Fujisawa T., Fujita K., et al.  Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci. 2007;105:151–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17928738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francque S.M., Bedossa P., Ratziu V., Anstee Q.M., Bugianesi E., Sanyal A.J., et al.  A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547–1558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34670042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L., et al.  Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–1159 e1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26874076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W., Kim B.G., Lee J.S., Lee C.K., Yeon J.E., Chang M.S., et al.  Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45:1073–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28225186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4447192</ArticleId>
            <ArticleId IdType="pubmed">25468160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowdley K.V., Vuppalanchi R., Levy C., Floreani A., Andreone P., LaRusso N.F., et al.  A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73:94–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8157171</ArticleId>
            <ArticleId IdType="pubmed">32165251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traussnigg S., Halilbasic E., Hofer H., Munda P., Stojakovic T., Fauler G., et al.  Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wien Klin Wochenschr. 2021;133:441–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8116226</ArticleId>
            <ArticleId IdType="pubmed">32930860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison S.A., Bashir M.R., Lee K.J., Shim-Lopez J., Lee J., Wagner B., et al.  A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021;75:25–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33581174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pockros P.J., Fuchs M., Freilich B., Schiff E., Kohli A., Lawitz E.J., et al.  CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39:2082–2093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31402538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y., Wei Q., Liu Y., Yuan J. The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver. Biochem Biophys Res Commun. 2021;580:1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34607257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rohrbach T.D., Asgharpour A., Maczis M.A., Montefusco D., Cowart L.A., Bedossa P., et al.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice. J Lipid Res. 2019;60:1311–1322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6602124</ArticleId>
            <ArticleId IdType="pubmed">31110049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jose C., Hebert-Chatelain E., Bellance N., Larendra A., Su M., Nouette-Gaulain K., et al.  AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta. 2011;1807:707–718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21692240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C., Sheng L., Yuan M., Hu J., Meng Y., Wu Y., et al.  Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met. Toxicol Appl Pharmacol. 2020;392:114918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32045588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You B.J., Chen L.Y., Hsu P.H., Sung P.H., Hung Y.C., Lee H.Z. Orlistat displays antitumor activity and enhances the efficacy of paclitaxel in human hepatoma Hep3B cells. Chem Res Toxicol. 2019;32:255–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30667213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y., Lin L.P., Zhu C.H., Chen Y., Hou Y.T., Ding J. Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther. 2006;5:978–985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16855382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miranda J.F., Scarinci L.D., Ramos L.F., Silva C.M., Goncalves L.R., de Morais P.F., et al.  The modulatory effect of triclosan on the reversion of the activated phenotype of LX-2 hepatic stellate cells. J Biochem Mol Toxicol. 2020;34:e22413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31714634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C.H., Tsai S.J., Wang Y.J., Pan M.H., Kao J.Y., Way T.D. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res. 2009;53:1156–1165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19662644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Lima Luna A.C., Forti F.L. Modulation of SCD1 activity in hepatocyte cell lines: evaluation of genomic stability and proliferation. Mol Cell Biochem. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou Y., Zhong L., Yu S., Shen W., Cai C., Yu H. Inhibition of stearoyl-coenzyme A desaturase 1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy. Aging (Albany NY) 2020;12:7350–7362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7202503</ArticleId>
            <ArticleId IdType="pubmed">32324591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park H.R., Yoo M.Y., Seo J.H., Kim I.S., Kim N.Y., Kang J.Y., et al.  Sesquiterpenoids isolated from the flower buds of Tussilago farfara L. inhibit diacylglycerol acyltransferase. J Agric Food Chem. 2008;56:10493–10497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18937486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lencioni R., Marrero J., Venook A., Ye S.L., Kudo M. Design and rationale for the non-interventional global investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) study. Int J Clin Pract. 2010;64:1034–1041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2905618</ArticleId>
            <ArticleId IdType="pubmed">20642705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G., Kuang S., Cao R., Wang J., Peng Q., Sun C. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway. FASEB J. 2019;33:10089–10103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31199678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma M.K.F., Lau E.Y.T., Leung D.H.W., Lo J., Ho N.P.Y., Cheng L.K.W., et al.  Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Hepatol. 2017;67:979–990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28647567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu A., Wang B., Fu J., Qin W., Yu T., Yang Z., et al.  Diet-induced hepatic steatosis activates Ras to promote hepatocarcinogenesis via CPT1alpha. Cancer Lett. 2019;442:40–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30401637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merrill C.L., Ni H., Yoon L.W., Tirmenstein M.A., Narayanan P., Benavides G.R., et al.  Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci. 2002;68:93–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12075114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren M., Xu H., Xia H., Tang Q., Bi F. Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis. Cell Death Discov. 2021;7:125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8164629</ArticleId>
            <ArticleId IdType="pubmed">34052835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F., Feng F., Wang L., Wang X., Li Z., Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis. 2019;10:672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6739379</ArticleId>
            <ArticleId IdType="pubmed">31511501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cariello M., Peres C., Zerlotin R., Porru E., Sabba C., Roda A., et al.  Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-/-) mice. Sci Rep. 2017;7:11203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5593831</ArticleId>
            <ArticleId IdType="pubmed">28894223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J., Dai W., Mao Y., Wu L., Li J., Chen K., et al.  Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020;39:24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6993409</ArticleId>
            <ArticleId IdType="pubmed">32000827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jouve J.L., Lecomte T., Bouche O., Barbier E., Khemissa Akouz F., Riachi G., et al.  Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:516–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31125576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding X., Chaiteerakij R., Moser C.D., Shaleh H., Boakye J., Chen G., et al.  Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016;7:20080–20092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4991440</ArticleId>
            <ArticleId IdType="pubmed">26956050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding X., Zhang Y., Huang T., Xu G., Peng C., Chen G., et al.  Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. Am J Cancer Res. 2019;9:546–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6448062</ArticleId>
            <ArticleId IdType="pubmed">30949409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beljanski V., Lewis C.S., Smith C.D. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011;11:524–534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3087901</ArticleId>
            <ArticleId IdType="pubmed">21258214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lozano E., Monte M.J., Briz O., Hernandez-Hernandez A., Banales J.M., Marin J.J., et al.  Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT) J Control Release. 2015;216:93–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26278512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Matteo S., Nevi L., Costantini D., Overi D., Carpino G., Safarikia S., et al.  The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PLoS One. 2019;14:e0210077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6345424</ArticleId>
            <ArticleId IdType="pubmed">30677052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran Q., Lee H., Kim C., Kong G., Gong N., Kwon S.H., et al.  Revisiting the Warburg effect: diet-based strategies for cancer prevention. Biomed Res Int. 2020;2020:8105735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7426758</ArticleId>
            <ArticleId IdType="pubmed">32802877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae J.S., Park J.M., Lee J., Oh B.C., Jang S.H., Lee Y.B., et al.  Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice. Metabolism. 2017;66:32–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27923447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemoto N., Suzuki S., Kikuchi H., Okabe H., Sassa S., Sakamoto S. Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. In Vivo. 2009;23:685–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19779101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konuma K., Itoh M., Suganami T., Kanai S., Nakagawa N., Sakai T., et al.  Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One. 2015;10:e0121528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4376873</ArticleId>
            <ArticleId IdType="pubmed">25816330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M., Sun K., Guo M., Gao H., Liu K., Yang C., et al.  Fish consumption and n-3 polyunsaturated fatty acids, and risk of hepatocellular carcinoma: systematic review and meta-analysis. Cancer Causes Control. 2015;26:367–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25534918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang S., Huang J., Lee B.K., Jung Y.S., Im E., Koh J.M., et al.  Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120) Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:105–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29126901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weylandt K.H., Krause L.F., Gomolka B., Chiu C.Y., Bilal S., Nadolny A., et al.  Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-alpha. Carcinogenesis. 2011;32:897–903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3106436</ArticleId>
            <ArticleId IdType="pubmed">21421544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeyapal S., Kona S.R., Mullapudi S.V., Putcha U.K., Gurumurthy P., Ibrahim A. Substitution of linoleic acid with alpha-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis. Sci Rep. 2018;8:10953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6053361</ArticleId>
            <ArticleId IdType="pubmed">30026586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valenzuela R., Espinosa A., Gonzalez-Manan D., D'Espessailles A., Fernandez V., Videla L.A., et al.  N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One. 2012;7:e46400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3474802</ArticleId>
            <ArticleId IdType="pubmed">23082120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Q., Tan Y., Yin P., Ye G., Gao P., Lu X., et al.  Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013;73:4992–5002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23824744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon J., Ouro A., Ala-Ibanibo L., Presa N., Delgado T.C., Martinez-Chantar M.L. Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover. Int J Mol Sci. 2019;21</Citation>
        </Reference>
        <Reference>
          <Citation>Lim K., Han C., Dai Y., Shen M., Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther. 2009;8:3046–3055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2783299</ArticleId>
            <ArticleId IdType="pubmed">19887546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patterson A.D., Maurhofer O., Beyoglu D., Lanz C., Krausz K.W., Pabst T., et al.  Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011;71:6590–6600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3206149</ArticleId>
            <ArticleId IdType="pubmed">21900402</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
